Iminostilbene

Iminostilbene is a chemical precursor of carbamazepine. Additionally, Iminostilbene is an orally active inhibitor of PKM2 (Pyruvate Kinase M2) and COX2 (Cyclooxygenase-2). Iminostilbene exerts its effects by inhibiting PKM2 and its interaction with HIF-1α and STAT3, reducing COX2 and iNOS expression, and decreasing LPS-induced release of IL-1β, IL-6, TNF-α, and MCP-1, thereby suppressing macrophage-mediated inflammatory responses and improving myocardial ischemia/reperfusion (MI/R) injury. Iminostilbene holds promise for research in inflammation regulation, cardiovascular diseases (such as MI/R injury), and macrophage-mediated immune-related diseases^[1][2]. In Vitro:Iminostilbene (2.5-10 μM, 30 h) inhibits LPS-induced inflammatory response, reduces PKM2 expression, and suppresses its downstream signaling pathways in RAW264.7 macrophages^[2]. In Vivo:Iminostilbene (0.625 mg/kg, 1.25 mg/kg, p.o., once daily for 5 days) improved cardiac function and suppressed inflammation in the myocardial ischemia/reperfusion (MI/R) injury SD rat model^[2].